Autopsy report · NCT04483544

Pembrolizumab and Olaparib in Cervical Cancer Patients

“Poor accrual related to change in standard of care treatment for this population.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 4 years before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Baptist Health South Florida

Sponsor type

University, hospital or other

Conditions

Cervical Cancer; Cervical Carcinoma

Interventions

pembrolizumab; olaparib

Participants

8

Sites

2

Countries

United States

Trials that died the same way

• Pre-op Paravertebral Blocks to Decrease Post-op Pain Following Mastectomy With Immediate Tissue Expander (TE) Reconstruction
  “Poor accrual due to change in standard of care procedure.” (88% match in meaning)
• Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study
  “poor patient accrual” (74% match in meaning)
• Dose-adjusted EPOCH-R in MYC Positive DLBCL
  “Poor accrual of eligible patients” (73% match in meaning)
• Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
  “Inadequate patient accrual” (69% match in meaning)
• Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
  “lack of patient population - slow accrual” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.